XML 149 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation (Tables)
6 Months Ended
Jun. 27, 2020
Share-based Payment Arrangement [Abstract]  
Summary of Equity Awards Activity
A summary of the equity awards available for future grants under the 2018 Plan is as follows:

Available for future grants as of December 31, 20193,484,960  
Granted(268,235) 
Cancellation and forfeitures986  
Available for future grants as of June 27, 20203,217,711  
Schedule of Compensation Expense and Related Income Tax benefit
The compensation expense from the Company’s share-based compensation plans and associated income tax benefit, excluding the effects of excess tax benefits or shortfalls, were included in the Consolidated Statements of Operations as follows (in millions):

Three Months EndedSix Months Ended
Compensation costs and related income tax benefitJune 27, 2020June 29, 2019June 27, 2020June 29, 2019
Cost of sales$ $ $ $ 
Selling and marketing    
Research and development    
General and administration   13  
Total compensation expense$17  $18  $23  $31  
Income tax benefit$ $ $ $ 
Summary of SARs Activity
A summary of the Company’s SARs for the six months ended June 27, 2020 is as follows:
SARsSARsWeighted-Average Grant Date Exercise Price
Outstanding at beginning of period896,923  $89.05  
Granted64,727  244.97  
Exercised(178,625) 73.21  
Forfeited(8,954) 89.57  
Outstanding at end of period774,071  $105.70  
Exercisable at end of period533,880  $77.28  
Weighted-Average Assumptions Used for Grants of SARs
The following table shows the weighted-average assumptions used for grants of SARs, as well as the fair value of the grants based on those assumptions:
June 27,
2020
June 29,
2019
Expected dividend yield0%0%
Forfeiture rate8.00%8.20%
Volatility42.51%36.79%
Risk free interest rate0.24%2.28%
Expected weighted-average life4.004.02
Weighted-average grant date fair value of SARs granted
(per underlying share)
$79.47$64.17
Schedule of Outstanding and Exercisable Options The following table summarizes information about SARs outstanding as of June 27, 2020:
OutstandingExercisable
Aggregate intrinsic value (in millions)$109  $90  
Weighted-average remaining contractual life4.74.4
Summary of Restricted Stock Award Activity
A summary of the Company’s RSAs for the six months ended June 27, 2020 is as follows:
RSAsSharesWeighted-Average
Grant Date Fair Value
Outstanding at beginning of period434,641  $151.52  
Granted145,299  244.01
Released(268,063) 132.61
Forfeited(6,697) 159.57
Outstanding at end of period305,180  $211.69  
Summary of Performance Share Award Activity
The fair value of each PSA granted includes assumptions around the Company’s performance goals. A summary of the
Company’s PSAs for the six months ended June 27, 2020 is as follows:
PSAsSharesWeighted-Average
Grant Date Fair Value
Outstanding at beginning of period170,749  $144.47  
Granted98,174  239.44
Released(129,344) 159.76
Forfeited(280) 204.76
Outstanding at end of period139,299  $198.21